Genelux Corporation (NASDAQ:GNLX) Stock Has Consensus Price Target of $18.00 According to Analysts

Shares of Genelux Corporation (NASDAQ:GNLX) have been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $18.00.

GNLX has been the topic of a number of recent research reports. Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a research report on Tuesday, August 18th. Lucid Cap Mkts upgraded Genelux to a “strong-buy” rating in a research note on Wednesday, September 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Finally, Wall Street Zen lowered Genelux from a “sell” rating to a “strong sell” rating in a report on Monday.

Insider Activity

In other news, insider Yong Yu sold 9,683 shares of Genelux stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.75, for a total value of $26,628.25. Following the completion of the transaction, the insider owned 258,688 shares in the company, valued at approximately $711,392. This trade represents a 3.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas Zindrick sold 34,463 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.67, for a total value of $92,016.21. Following the transaction, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at approximately $3,274,560.09. This represents a 2.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 47,822 shares of company stock worth $129,482. 7.50% of the stock is owned by company insiders.

Institutional Trading of Genelux

A number of large investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new stake in shares of Genelux in the 2nd quarter valued at about $35,000. Strive Financial Group LLC grew its stake in Genelux by 728.7% during the 2nd quarter. Strive Financial Group LLC now owns 41,437 shares of the company’s stock worth $125,000 after buying an additional 36,437 shares during the last quarter. SteelPeak Wealth LLC grew its stake in Genelux by 458.9% during the 1st quarter. SteelPeak Wealth LLC now owns 60,895 shares of the company’s stock worth $147,000 after buying an additional 50,000 shares during the last quarter. AMG National Trust Bank acquired a new position in Genelux during the second quarter worth approximately $227,000. Finally, Citadel Advisors LLC acquired a new position in Genelux during the second quarter worth approximately $257,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Stock Down 1.2%

Shares of GNLX opened at $2.52 on Wednesday. Genelux has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The firm’s 50 day moving average price is $2.58 and its 200 day moving average price is $2.75. The company has a market cap of $114.00 million, a P/E ratio of -2.93 and a beta of 0.59.

Genelux (NASDAQ:GNLX) last released its earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Research analysts forecast that Genelux will post -0.81 earnings per share for the current year.

Genelux Company Profile

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel cancer treatments based on oncolytic virus immunotherapies. The company’s platform is designed to use genetically modified viruses to selectively infect and destroy tumor cells while stimulating the patient’s immune system to recognize and attack cancer.

Genelux’s lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified vaccinia virus being studied in combination with other therapies for advanced solid tumors.